Last Updated: November 8, 2026

Legacy Company Profile

« Back to Dashboard

What is the competitive landscape for LEGACY

LEGACY has twenty-four approved drugs.

There are twenty-nine US patents protecting LEGACY drugs.

Summary for Legacy

US Patents:	29
Tradenames:	17
Ingredients:	15
NDAs:	24

Drugs and US Patents for Legacy

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Legacy	BETAPACE AF	sotalol hydrochloride	TABLET;ORAL	021151-001	Feb 22, 2000	AB	RX	Yes	No		⤷ Start Trial				⤷ Start Trial
Legacy	ESBRIET	pirfenidone	TABLET;ORAL	208780-001	Jan 11, 2017	AB	RX	Yes	No	8,420,674	⤷ Start Trial				⤷ Start Trial
Legacy	CLODERM	clocortolone pivalate	CREAM;TOPICAL	017765-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	No		⤷ Start Trial				⤷ Start Trial
Legacy	ESBRIET	pirfenidone	CAPSULE;ORAL	022535-001	Oct 15, 2014	AB	RX	Yes	Yes	8,609,701	⤷ Start Trial				⤷ Start Trial
Legacy	BETAPACE	sotalol hydrochloride	TABLET;ORAL	019865-001	Oct 30, 1992	AB	RX	Yes	No		⤷ Start Trial				⤷ Start Trial
Legacy	ESBRIET	pirfenidone	TABLET;ORAL	208780-002	Jan 11, 2017		DISCN	Yes	No	8,592,462	⤷ Start Trial				⤷ Start Trial
Legacy	ESBRIET	pirfenidone	TABLET;ORAL	208780-003	Jan 11, 2017	AB	RX	Yes	Yes	8,084,475	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Legacy

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Legacy	ETHYOL	amifostine	INJECTABLE;INJECTION	020221-002	Sep 10, 1999	5,424,471	⤷ Start Trial
Legacy	LOTRONEX	alosetron hydrochloride	TABLET;ORAL	021107-001	Feb 9, 2000	6,284,770	⤷ Start Trial
Legacy	ZANAFLEX	tizanidine hydrochloride	CAPSULE;ORAL	021447-003	Aug 29, 2002	6,455,557	⤷ Start Trial
Legacy	NAFTIN	naftifine hydrochloride	GEL;TOPICAL	019356-001	Jun 18, 1990	4,828,251	⤷ Start Trial
Legacy	MOTOFEN	atropine sulfate; difenoxin hydrochloride	TABLET;ORAL	017744-002	Approved Prior to Jan 1, 1982	3,646,207	⤷ Start Trial
Legacy	ESBRIET	pirfenidone	TABLET;ORAL	208780-002	Jan 11, 2017	9,561,217	⤷ Start Trial
Legacy	RIDAURA	auranofin	CAPSULE;ORAL	018689-001	May 24, 1985	3,635,945	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for LEGACY drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Capsules	7.5 mg	➤ Subscribe	2014-04-07
➤ Subscribe	Capsules	2 mg, 4 mg and 6 mg	➤ Subscribe	2007-08-10
➤ Subscribe	Tablets	0.5 mg and 1 mg	➤ Subscribe	2010-12-02
➤ Subscribe	Tablets	267 mg, 534 mg and 801 mg	➤ Subscribe	2018-10-15
➤ Subscribe	For Injection	500 mg/vial	➤ Subscribe	2004-04-16

International Patents for Legacy Drugs

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Chile	2011000966	⤷ Start Trial
Slovenia	1940364	⤷ Start Trial
Ukraine	96770	⤷ Start Trial
Peru	20110683	⤷ Start Trial
Japan	2015526528	⤷ Start Trial
South Korea	102552615	⤷ Start Trial
Ukraine	115861	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Legacy Drugs

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0809498	SPC/GB10/012	United Kingdom	⤷ Start Trial	PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
0809498	10C0038	France	⤷ Start Trial	PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Legacy

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.